Peter Olson

15.0k total citations · 6 hit papers
86 papers, 8.3k citations indexed

About

Peter Olson is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Olson has authored 86 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 33 papers in Oncology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Olson's work include Pancreatic and Hepatic Oncology Research (9 papers), Peroxisome Proliferator-Activated Receptors (8 papers) and Cancer Genomics and Diagnostics (5 papers). Peter Olson is often cited by papers focused on Pancreatic and Hepatic Oncology Research (9 papers), Peroxisome Proliferator-Activated Receptors (8 papers) and Cancer Genomics and Diagnostics (5 papers). Peter Olson collaborates with scholars based in United States, France and Israel. Peter Olson's co-authors include Douglas Hanahan, Ronald M. Evans, Morgan Truitt, Neta Erez, Chih‐Hao Lee, Jerrold M. Olefsky, Andrea L. Hevener, Jamie Le, Yaacov Barak and Michael C. Nelson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Peter Olson

83 papers receiving 8.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner

2010 1.2k citations Morgan Truitt, Peter Olson et al. profile →
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

2011 1.2k citations Peter Olson, Morgan Truitt et al. Nature Medicine profile →
Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle

2003 811 citations Yaacov Barak, Andrea L. Hevener et al. Proceedings of the National Academy of Sciences profile →
Minireview: Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors

2003 742 citations Chih‐Hao Lee, Peter Olson et al. profile →
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer

2006 506 citations Nabeel Bardeesy, Kuang‐Hung Cheng et al. Genes & Development profile →
Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer

2015 381 citations Andrew J. Gunderson, Megan M. Kaneda et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Olson United States	31	4.4k	3.3k	1.9k	1.4k	1.1k	86	8.3k
Isabel Fabregat Spain	53	4.8k 1.1×	2.4k 0.7×	1.4k 0.7×	735 0.5×	1.1k 1.0×	168	8.8k
Gerald Höefler Austria	50	4.2k 0.9×	2.1k 0.6×	2.3k 1.2×	2.3k 1.6×	705 0.6×	192	9.3k
Peter C. Lucas United States	43	4.2k 0.9×	1.8k 0.5×	2.4k 1.2×	834 0.6×	1.7k 1.6×	163	8.4k
Rugang Zhang United States	51	5.8k 1.3×	2.0k 0.6×	1.3k 0.7×	1.4k 1.0×	1.3k 1.2×	145	8.4k
Atsushi Hirao Japan	44	7.2k 1.6×	3.2k 1.0×	1.9k 1.0×	1.0k 0.7×	2.4k 2.1×	132	12.4k
Roberta Maestro Italy	42	4.9k 1.1×	2.9k 0.9×	1.5k 0.8×	901 0.6×	914 0.8×	121	8.5k
Hiroki Kuniyasu Japan	54	5.4k 1.2×	3.1k 0.9×	2.2k 1.2×	730 0.5×	1.0k 0.9×	277	10.3k
Wolter J. Mooi Netherlands	43	5.8k 1.3×	4.5k 1.4×	2.0k 1.0×	2.8k 2.0×	1.6k 1.5×	111	12.0k
Hui‐Kuan Lin United States	53	7.6k 1.7×	2.3k 0.7×	2.4k 1.3×	845 0.6×	1.1k 0.9×	120	10.7k
Joji Kitayama Japan	49	2.9k 0.7×	2.7k 0.8×	1.4k 0.7×	389 0.3×	857 0.8×	195	7.4k

Countries citing papers authored by Peter Olson

Since Specialization

Citations

This map shows the geographic impact of Peter Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Olson more than expected).

Fields of papers citing papers by Peter Olson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Olson. The network helps show where Peter Olson may publish in the future.

Co-authorship network of co-authors of Peter Olson

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Olson. A scholar is included among the top collaborators of Peter Olson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Olson. Peter Olson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sudhakar, Niranjan, Jade Laguer, David M. Briere, et al.. (2024). Abstract 7268: The SOS1 inhibitor MRTX0902 demonstrates activity across cancer models with mutations in proximal components of the RAS-MAPK pathway. Cancer Research. 84(6_Supplement). 7268–7268.

Edwards, A. Cole, Clint A. Stalnecker, Jennifer E. Klomp, et al.. (2023). TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors. Cancer Research. 83(24). 4112–4129. 33 indexed citations

Sudhakar, Niranjan, Jade Laguer, David M. Briere, et al.. (2023). Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC. Cancer Research. 83(7_Supplement). 3499–3499.

He, Kai, David Berz, Shirish M. Gadgeel, et al.. (2023). MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of Thoracic Oncology. 18(7). 907–921. 20 indexed citations

Sabari, Joshua K., Vamsidhar Velcheti, K. Shimizu, et al.. (2022). Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 28(15). 3318–3328. 78 indexed citations

Briere, David M., Shuai Li, Andrew Calinisan, et al.. (2021). The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. Molecular Cancer Therapeutics. 20(6). 975–985. 109 indexed citations

Spira, Alexander I., Collin M. Blakely, Kai He, et al.. (2018). Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. Annals of Oncology. 29. viii400–viii401. 9 indexed citations

Xu, Ai‐Min, Cathy C. Zhang, Peter Olson, et al.. (2017). Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3. Molecular Cancer Therapeutics. 16(8). 1531–1543. 60 indexed citations

Wang, Kai, Qin Zhang, Danan Li, et al.. (2015). PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor. Clinical Cancer Research. 21(6). 1487–1496. 122 indexed citations

10.

Gunderson, Andrew J., Megan M. Kaneda, Takahiro Tsujikawa, et al.. (2015). Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discovery. 6(3). 270–285. 381 indexed citations breakdown →

11.

Farber, Nicholas, Mark Doyle, Geetha Rayarao, et al.. (2014). Ex vivo cardiovascular magnetic resonance measurements of right and left ventricular mass compared with direct mass measurement in excised hearts after transplantation: a first human SSFP comparison. Journal of Cardiovascular Magnetic Resonance. 16(1). 74–74. 34 indexed citations

12.

El-Gohary, Yasser, Jan F. Silverman, Peter Olson, et al.. (2007). Endoglin (CD105) and Vascular Endothelial Growth Factor as Prognostic Markers in Prostatic Adenocarcinoma. American Journal of Clinical Pathology. 127(4). 572–579. 103 indexed citations

13.

Lee, Chih‐Hao, Peter Olson, Andrea L. Hevener, et al.. (2006). PPARδ regulates glucose metabolism and insulin sensitivity. Proceedings of the National Academy of Sciences. 103(9). 3444–3449. 402 indexed citations

14.

Bardeesy, Nabeel, Kuang‐Hung Cheng, Justin H. Berger, et al.. (2006). Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes & Development. 20(22). 3130–3146. 506 indexed citations breakdown →

15.

Hevener, Andrea L., Weimin He, Yaacov Barak, et al.. (2003). Muscle-specific Pparg deletion causes insulin resistance. Nature Medicine. 9(12). 1491–1497. 412 indexed citations

16.

Olson, Peter, Jan F. Silverman, & Celeste N. Powers. (2000). Pleural fluid cytology of Hodgkin's disease: Cytomorphologic features and the value of immunohistochemical studies. Diagnostic Cytopathology. 22(1). 21–24. 12 indexed citations

17.

Shuman, Barry A., et al.. (1997). Histological Presence of Viable Prostatic Glands on Routine Biopsy Following Cryosurgical Ablation of the Prostate. The Journal of Urology. 157(2). 552–555. 23 indexed citations

18.

Fogelman, Alan M. & Peter Olson. (1996). Medicine chairs' views on the impact of managed care on departments of internal medicine. The American Journal of Medicine. 101(4). 331–337. 1 indexed citations

19.

Olson, Peter, Carol Cox, & Jeffrey McCullough. (1977). Laboratory and Clinical Effects of the Infusion ofACD Solution During Plateletpheresis. Vox Sanguinis. 33(2). 79–87. 4 indexed citations

20.

Olson, Peter & Lee W. Wattenberg. (1969). Inhibition by 5-Fluorouracil of the Early Stages of Chemical Carcinogenesis in Mouse Skin. Experimental Biology and Medicine. 131(4). 1135–1137. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact